BUSINESSCNBC TOP
Novo Nordisk's raised forecast fails to change the debate over its obesity business
Novo Nordisk raised its forecast for its obesity business, but Wall Street remains unconvinced about its ability to achieve sustainable growth amid intensifying competition from Eli Lilly.
Related Signal
Adjacent reporting
- Novo Nordisk Slides as Forecast Boost Fails to Impress
- Novo Nordisk’s next obesity battlefront: Winning beyond America
- Novo Nordisk is raising its full-year outlook as its weight loss pill keeps selling
- Novo Nordisk Shares Surge on New Obesity Drug Results
- Novo sues Lilly amid escalating weight-loss rivalry
- STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price